Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Environment

Disregarding Nuclear Energy

March 30, 2015 | A version of this story appeared in Volume 93, Issue 13

March 9, page 16: TaiGen Biotechnology has initiated Phase II clinical trials of burixafor in China for use in chemotherapy sensitization in leukemia patients. The trials are not yet complete.

Although the article was published several years ago, “Reintroducing Thorium” was an interesting story (C&EN, Nov. 16, 2009, page 44). I have kept this article all these years and have been waiting to see whether some of the promises it holds come to fruition.

Having seen nothing on thorium technology since then, I find that Lightbridge Corp. is the company behind its development. Things have progressed slowly, and its stock has not done well. It is understandable that with gas and petroleum supplies currently in abundance, nuclear energy is not high on the list as an energy source. Unfortunately, we continue to pump CO2 into the atmosphere while ignoring an abundant and relatively safe nuclear option.

David Koster
Carbondale, Ill.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.